Association of urinary TXB2 levels with all-cause mortality among prostate cancer patients
| TXB2 . | All cases . | African American . | European American . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Alive, No. (%) . | Dead, No. (%) . | HR (95% CI)a . | Alive, No. (%) . | Dead, No. (%) . | HR (95% CI)a . | Alive, No. (%) . | Dead, No. (%) . | HR (95% CI)a . | |
| ≤Medianb | 313 (43.6) | 82 (33.2) | Ref | 153 (44.3) | 39 (28.7) | Ref | 160 (42.9) | 43 (39.6) | Ref |
| >Median | 396 (56.4) | 158 (66.8) | 1.33 (0.99 to 1.79) | 186 (55.7) | 95 (71.3) | 1.59 (1.06 to 2.40) | 210 (57.1) | 63 (60.4) | 1.11 (0.70 to 1.76) |
| Continuousc | — | — | 1.24 (1.09 to 1.41) | — | — | 1.31 (1.10 to 1.56) | — | — | 1.21 (1.01 to 1.45) |
| TXB2 . | All cases . | African American . | European American . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Alive, No. (%) . | Dead, No. (%) . | HR (95% CI)a . | Alive, No. (%) . | Dead, No. (%) . | HR (95% CI)a . | Alive, No. (%) . | Dead, No. (%) . | HR (95% CI)a . | |
| ≤Medianb | 313 (43.6) | 82 (33.2) | Ref | 153 (44.3) | 39 (28.7) | Ref | 160 (42.9) | 43 (39.6) | Ref |
| >Median | 396 (56.4) | 158 (66.8) | 1.33 (0.99 to 1.79) | 186 (55.7) | 95 (71.3) | 1.59 (1.06 to 2.40) | 210 (57.1) | 63 (60.4) | 1.11 (0.70 to 1.76) |
| Continuousc | — | — | 1.24 (1.09 to 1.41) | — | — | 1.31 (1.10 to 1.56) | — | — | 1.21 (1.01 to 1.45) |
Unconditional Cox regression adjusted for age at study entry, body mass index (kg/m2), diabetes (no or yes), aspirin (no or yes), education (high school or less, some college, college, professional school), family history of prostate cancer (first-degree relatives, yes or no), self-reported race (not included in stratified analysis), smoking history (never, former, current), treatment (0 = none, 1 = surg, 2 = radiation, 3 = hormone, 4 = combination), disease stage (1= stage I, 2 = stage IIA and IIB, 3 = stage III, 4 = stage IV), and Gleason score (0 = Gleason ≤7 and 1 = Gleason >7). CI = confidence interval; OR= odds ratio; Ref = reference.
Median cutoff point is 0.505 ng TXB2/mg creatinine.
TXB2 as a continuous, log2-transformed variable.
Association of urinary TXB2 levels with all-cause mortality among prostate cancer patients
| TXB2 . | All cases . | African American . | European American . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Alive, No. (%) . | Dead, No. (%) . | HR (95% CI)a . | Alive, No. (%) . | Dead, No. (%) . | HR (95% CI)a . | Alive, No. (%) . | Dead, No. (%) . | HR (95% CI)a . | |
| ≤Medianb | 313 (43.6) | 82 (33.2) | Ref | 153 (44.3) | 39 (28.7) | Ref | 160 (42.9) | 43 (39.6) | Ref |
| >Median | 396 (56.4) | 158 (66.8) | 1.33 (0.99 to 1.79) | 186 (55.7) | 95 (71.3) | 1.59 (1.06 to 2.40) | 210 (57.1) | 63 (60.4) | 1.11 (0.70 to 1.76) |
| Continuousc | — | — | 1.24 (1.09 to 1.41) | — | — | 1.31 (1.10 to 1.56) | — | — | 1.21 (1.01 to 1.45) |
| TXB2 . | All cases . | African American . | European American . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Alive, No. (%) . | Dead, No. (%) . | HR (95% CI)a . | Alive, No. (%) . | Dead, No. (%) . | HR (95% CI)a . | Alive, No. (%) . | Dead, No. (%) . | HR (95% CI)a . | |
| ≤Medianb | 313 (43.6) | 82 (33.2) | Ref | 153 (44.3) | 39 (28.7) | Ref | 160 (42.9) | 43 (39.6) | Ref |
| >Median | 396 (56.4) | 158 (66.8) | 1.33 (0.99 to 1.79) | 186 (55.7) | 95 (71.3) | 1.59 (1.06 to 2.40) | 210 (57.1) | 63 (60.4) | 1.11 (0.70 to 1.76) |
| Continuousc | — | — | 1.24 (1.09 to 1.41) | — | — | 1.31 (1.10 to 1.56) | — | — | 1.21 (1.01 to 1.45) |
Unconditional Cox regression adjusted for age at study entry, body mass index (kg/m2), diabetes (no or yes), aspirin (no or yes), education (high school or less, some college, college, professional school), family history of prostate cancer (first-degree relatives, yes or no), self-reported race (not included in stratified analysis), smoking history (never, former, current), treatment (0 = none, 1 = surg, 2 = radiation, 3 = hormone, 4 = combination), disease stage (1= stage I, 2 = stage IIA and IIB, 3 = stage III, 4 = stage IV), and Gleason score (0 = Gleason ≤7 and 1 = Gleason >7). CI = confidence interval; OR= odds ratio; Ref = reference.
Median cutoff point is 0.505 ng TXB2/mg creatinine.
TXB2 as a continuous, log2-transformed variable.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
